Survodutide
Also known as: BI 456906, Glucagon/GLP-1 dual agonist
Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Benefits
6
Conditions
4
Evidence
Phase 2 trials for obesity and MASH+ studies
Source
Synthetic glucagon/GLP-1 dual agonist
Gabriel Brain Score
Strong
Overview
Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Mechanism of Action
Dual agonist of glucagon and GLP-1 receptors, increases energy expenditure and fat oxidation via glucagon pathway, reduces appetite and improves insulin secretion via GLP-1, targets liver fat reduction and metabolic health.
Key Benefits
- ✓Significant weight loss
- ✓Reduces liver fat (MASH treatment)
- ✓Increases energy expenditure
- ✓Improved metabolic parameters
- ✓Appetite suppression
- ✓Potential for liver fibrosis reduction
Clinical Applications
Dosing Guidelines
Subcutaneous injection
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
Phase 2 trials for obesity and MASH
Phase 2 data shows 15-18% weight loss and significant liver fat reduction. Promising for MASH treatment where few options exist. Phase 3 trials ongoing for both obesity and MASH indications.
Safety Information
Potential Side Effects
- •Nausea
- •Diarrhea
- •Vomiting
- •Injection site reactions
- •Elevated heart rate (mild)
Contraindications
- Under investigation
Interactions
- ⚠Under investigation
Quick Facts
Related Peptides
Retatrutide
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.
Tirzepatide
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Semaglutide
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.